BCRX Q1 2023 Earnings — BioCryst Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

BCRXBioCryst Pharmaceuticals, Inc.

$2B

Q1 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$69M+37.8% YoY

Gross Profit

$68M98.6% margin

Operating Income

-$28M-41.3% margin

Net Income

-$53M-77.5% margin

EPS (Diluted)

$-0.28

QoQ Revenue Growth

-13.5%

Cash Flow

Operating Cash Flow

-$48M

Free Cash Flow

-$48M

Stock-Based Comp.

$14M

Balance Sheet

Total Assets

$510M

Total Liabilities

$838M

Stockholders' Equity

-$328M

Cash & Equivalents

$155M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$69M	$50M	+37.8%
Gross Profit	$68M	$50M	+36.5%
Operating Income	-$28M	-$50M	+43.1%
Net Income	-$53M	-$74M	+28.1%

Revenue Segments

Collaborative and Other Research and Development

$612,000100%